Literature DB >> 23697466

Reduction of motion sickness with an enhanced placebo instruction: an experimental study with healthy participants.

Björn Horing1, Katja Weimer, Damaris Schrade, Eric R Muth, Jenna L Scisco, Paul Enck, Sibylle Klosterhalfen.   

Abstract

OBJECTIVE: Expectancy and conditioning are underlying mechanisms of placebo and nocebo responses. In previous studies with motion sickness, we could induce nocebo responses by both methods, but no placebo responses.
METHODS: In Experiment 1, 64 volunteers (50% women, mean age = 23.5 years) were evaluated to determine the degree they realized speed changes in nauseogenic rotation. For Experiment 2, 32 volunteers (50% women, mean age = 26.0 years) were exposed to fast rotation (15 rounds per minute, or rpm) on Day 1. On Day 2, they either received a drink with a presumed effective antiemetic (actually placebo) or were told they belonged to the control group. Rotation was surreptitiously reduced (to 10 rpm). On Day 3, they were tested with the initial rotation speed. Outcome variables in both experiments were symptom ratings; additionally in Experiment 2, the number of nauseogenic head movements, tolerated rotation time, and electrogastrogram were analyzed for changes between Days 1 and 2 (expectancy plus speed reduction) and Days 1 and 3 (expectancy plus conditioning).
RESULTS: In Experiment 1, a dose-response function was established for different rotation speeds, with the smallest perceived difference between 10 and 15 rpm. In Experiment 2, placebo application induced better maximal symptom rating, head movement, and rotation time at Day 2 (F = 3.097, p = .043) and Day 3 (F = 3.401, p = .031). Electrogastrogram was unaffected.
CONCLUSIONS: Verbal suggestions combined with a conditioning procedure are effective in reducing symptoms of motion sickness.

Entities:  

Keywords:  conditioning; expectancy; motion sickness; nausea; placebo response; rotation

Mesh:

Substances:

Year:  2013        PMID: 23697466     DOI: 10.1097/PSY.0b013e3182915ee7

Source DB:  PubMed          Journal:  Psychosom Med        ISSN: 0033-3174            Impact factor:   4.312


  9 in total

Review 1.  The Neurophysiology and Treatment of Motion Sickness.

Authors:  Andreas Koch; Ingolf Cascorbi; Martin Westhofen; Manuel Dafotakis; Sebastian Klapa; Johann Peter Kuhtz-Buschbeck
Journal:  Dtsch Arztebl Int       Date:  2018-10-12       Impact factor: 5.594

Review 2.  [Psychophysiology of visceral pain].

Authors:  B Horing; P Enck
Journal:  Schmerz       Date:  2014-06       Impact factor: 1.107

Review 3.  Antihistamines for motion sickness.

Authors:  Nadine Karrim; Ryan Byrne; Nombulelo Magula; Yougan Saman
Journal:  Cochrane Database Syst Rev       Date:  2022-10-17

4.  How to study placebo responses in motion sickness with a rotation chair paradigm in healthy participants.

Authors:  Katja Weimer; Björn Horing; Eric R Muth; Paul Enck
Journal:  J Vis Exp       Date:  2014-12-14       Impact factor: 1.355

Review 5.  Prediction of placebo responses: a systematic review of the literature.

Authors:  Bjoern Horing; Katja Weimer; Eric R Muth; Paul Enck
Journal:  Front Psychol       Date:  2014-10-01

6.  A virtual experimenter to increase standardization for the investigation of placebo effects.

Authors:  Bjoern Horing; Nathan D Newsome; Paul Enck; Sabarish V Babu; Eric R Muth
Journal:  BMC Med Res Methodol       Date:  2016-07-18       Impact factor: 4.615

7.  Using Positive Attribute Framing to Attenuate Nocebo Side Effects: A Cybersickness Study.

Authors:  Alanna Mao; Kirsten Barnes; Louise Sharpe; Andrew L Geers; Suzanne G Helfer; Kate Faasse; Ben Colagiuri
Journal:  Ann Behav Med       Date:  2021-07-22

8.  Role of conditioning and verbal suggestion in placebo and nocebo effects on itch.

Authors:  Danielle J P Bartels; Antoinette I M van Laarhoven; Elise A Haverkamp; Oliver H Wilder-Smith; A Rogier T Donders; Henriët van Middendorp; Peter C M van de Kerkhof; Andrea W M Evers
Journal:  PLoS One       Date:  2014-03-19       Impact factor: 3.240

9.  Libertas: a phase II placebo-controlled study of NRL001 in patients with faecal incontinence showed an unexpected and sustained placebo response.

Authors:  L Siproudhis; W Graf; A Emmanuel; D Walker; R Ng Kwet Shing; C Pediconi; J Pilot; S Wexner; J Scholefield
Journal:  Int J Colorectal Dis       Date:  2016-04-13       Impact factor: 2.571

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.